Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NYSEARCA:LABD NYSEARCA:LABU NASDAQ:MDGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$83.99$76.77$14.30▼$84.55$11.83B1.262.56 million shs1.70 million shsLABDDirexion Daily S&P Biotech Bear 3x Shares$7.38$12.76$7.32▼$74.15$69.45M-2.385.23 million shs17.85 million shsLABUDirexion Daily S&P Biotech Bull 3x Shares$303.45$199.23$56.75▼$305.09$688.83M2.39626,698 shs523,223 shsMDGLMadrigal Pharmaceuticals$528.10$508.48$284.02▼$615.00$12.18B-1.05402,547 shs221,882 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals0.00%+6.46%+11.75%+37.62%+396.98%LABDDirexion Daily S&P Biotech Bear 3x Shares0.00%-9.67%-45.25%-53.29%-89.43%LABUDirexion Daily S&P Biotech Bull 3x Shares0.00%+9.88%+69.32%+76.79%+399.92%MDGLMadrigal Pharmaceuticals0.00%+3.01%+7.16%-3.44%+75.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$83.99$76.77$14.30▼$84.55$11.83B1.262.56 million shs1.70 million shsLABDDirexion Daily S&P Biotech Bear 3x Shares$7.38$12.76$7.32▼$74.15$69.45M-2.385.23 million shs17.85 million shsLABUDirexion Daily S&P Biotech Bull 3x Shares$303.45$199.23$56.75▼$305.09$688.83M2.39626,698 shs523,223 shsMDGLMadrigal Pharmaceuticals$528.10$508.48$284.02▼$615.00$12.18B-1.05402,547 shs221,882 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals0.00%+6.46%+11.75%+37.62%+396.98%LABDDirexion Daily S&P Biotech Bear 3x Shares0.00%-9.67%-45.25%-53.29%-89.43%LABUDirexion Daily S&P Biotech Bull 3x Shares0.00%+9.88%+69.32%+76.79%+399.92%MDGLMadrigal Pharmaceuticals0.00%+3.01%+7.16%-3.44%+75.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.69Moderate Buy$87.273.91% UpsideLABDDirexion Daily S&P Biotech Bear 3x Shares 0.00N/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x Shares 2.74Moderate Buy$303.45N/AMDGLMadrigal Pharmaceuticals 2.78Moderate Buy$687.9330.26% UpsideCurrent Analyst Ratings BreakdownLatest LABU, MDGL, ARWR, and LABD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026ARWRArrowhead Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.006/30/2026ARWRArrowhead Pharmaceuticals Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$90.006/24/2026MDGLMadrigal Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/17/2026ARWRArrowhead Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$61.00 ➝ $72.006/11/2026MDGLMadrigal Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$550.00 ➝ $542.006/1/2026MDGLMadrigal Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOverweight6/1/2026MDGLMadrigal Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/20/2026ARWRArrowhead Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)5/13/2026ARWRArrowhead Pharmaceuticals Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$35.00 ➝ $46.005/13/2026MDGLMadrigal Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$640.00 ➝ $709.005/8/2026ARWRArrowhead Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$80.00 ➝ $87.00(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$829.45M14.26$0.12 per share703.43$3.64 per share23.07LABDDirexion Daily S&P Biotech Bear 3x SharesN/AN/AN/AN/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AN/AN/AN/AN/AN/AMDGLMadrigal Pharmaceuticals$1.13B10.75N/AN/A$26.54 per share19.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$1.63M-$2.15N/AN/AN/A-48.38%-55.09%-18.13%8/6/2026 (Estimated)LABDDirexion Daily S&P Biotech Bear 3x SharesN/AN/AN/AN/AN/AN/AN/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AN/AN/AN/AN/AN/AN/AN/AN/AMDGLMadrigal Pharmaceuticals-$288.28M-$12.80N/A63.09N/A-27.32%-50.15%-25.44%8/4/2026 (Estimated)Latest LABU, MDGL, ARWR, and LABD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q2 2026ARWRArrowhead Pharmaceuticals-$1.0950-$0.93+$0.1650-$0.93$73.84 million$73.74 million5/6/2026Q1 2026MDGLMadrigal Pharmaceuticals-$3.61-$3.25+$0.36-$3.25$301.05 million$311.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/ALABDDirexion Daily S&P Biotech Bear 3x Shares$0.648.67%N/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x Shares$1.010.33%N/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals1.416.236.23LABDDirexion Daily S&P Biotech Bear 3x SharesN/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AN/AN/AMDGLMadrigal Pharmaceuticals0.633.503.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%LABDDirexion Daily S&P Biotech Bear 3x SharesN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AMDGLMadrigal Pharmaceuticals98.50%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals3.60%LABDDirexion Daily S&P Biotech Bear 3x SharesN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AMDGLMadrigal Pharmaceuticals17.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400140.86 million135.79 millionOptionableLABDDirexion Daily S&P Biotech Bear 3x SharesN/A9.41 millionN/ANot OptionableLABUDirexion Daily S&P Biotech Bull 3x SharesN/A2.27 millionN/ANot OptionableMDGLMadrigal Pharmaceuticals9023.06 million19.00 millionOptionableLABU, MDGL, ARWR, and LABD HeadlinesRecent News About These CompaniesMadrigal Pharmaceuticals, Inc. $MDGL Position Reduced by SG Americas Securities LLCJuly 4 at 4:23 AM | marketbeat.comRibo y Madrigal alcanzan un primer hito importante en el avance de nuevas terapias con siRNA para MASHJuly 2 at 4:00 AM | prnewswire.comRibo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASHJuly 1, 2026 | prnewswire.comMadrigal Pharmaceuticals (MDGL) Receives a Buy from JefferiesJuly 1, 2026 | theglobeandmail.comPictet Asset Management Holding SA Raises Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGLJune 29, 2026 | marketbeat.comAssenagon Asset Management S.A. Purchases 10,643 Shares of Madrigal Pharmaceuticals, Inc. $MDGLJune 29, 2026 | marketbeat.comMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)June 22, 2026 | globenewswire.comGroupama Asset Managment Boosts Stake in Madrigal Pharmaceuticals, Inc. $MDGLJune 19, 2026 | marketbeat.comJanus Henderson Group PLC Has $918.20 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGLJune 18, 2026 | marketbeat.comMadrigal Pharmaceuticals, Inc. $MDGL is Armistice Capital LLC's 5th Largest PositionJune 18, 2026 | marketbeat.comMadrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by Polar Capital Holdings PlcJune 17, 2026 | marketbeat.comMadrigal Pharmaceuticals, Inc. $MDGL Shares Sold by Avoro Capital Advisors LLCJune 17, 2026 | marketbeat.comAlkeon Capital Management LLC Acquires 120,000 Shares of Madrigal Pharmaceuticals, Inc. $MDGLJune 16, 2026 | marketbeat.comEntropy Technologies LP Increases Holdings in Madrigal Pharmaceuticals, Inc. $MDGLJune 15, 2026 | marketbeat.comMadrigal Pharmaceuticals, Inc. $MDGL Stock Position Raised by Lord Abbett & CO. LLCJune 13, 2026 | marketbeat.comMadrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by Castleark Management LLCJune 13, 2026 | marketbeat.comMadrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comThe Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data ReleaseJune 9, 2026 | finance.yahoo.comMadrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Bank of New York Mellon CorpJune 9, 2026 | marketbeat.comGoldman Sachs Group Inc. Trims Stock Position in Madrigal Pharmaceuticals, Inc. $MDGLJune 8, 2026 | marketbeat.comMadrigal Pharmaceuticals, Inc. $MDGL Shares Sold by Erste Asset Management GmbHJune 8, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLABU, MDGL, ARWR, and LABD Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$83.99 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$83.58 -0.41 (-0.49%) As of 07/2/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Direxion Daily S&P Biotech Bear 3x Shares NYSEARCA:LABD$7.38 0.00 (0.00%) As of 07/2/2026 04:10 PM EasternThe Direxion Daily S&P Biotech Bear 3X Shares (LABD) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times inverse exposure to the S&P Biotechnology Select Industry Index. LABD was launched on May 28, 2015 and is managed by Direxion.Direxion Daily S&P Biotech Bull 3x Shares NYSEARCA:LABU$303.45 0.00 (0.00%) As of 07/2/2026 04:10 PM EasternThe Direxion Daily S&P Biotech Bull 3X Shares (LABU) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times exposure to the S&P Biotechnology Select Industry Index. LABU was launched on May 28, 2015 and is managed by Direxion.Madrigal Pharmaceuticals NASDAQ:MDGL$528.10 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$527.50 -0.60 (-0.11%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
